insights_auto
Why is LYEL up 2,50%?
Dive Deeperchevron_right
LYEL:NASDAQ
Lyell Immunopharma Inc
8,19 US$
arrow_upward
+2,50%(+0,20) 1D
8,19 US$
0,00% (0,00)
bedtimeAfter hours
Closed: 15 ოქტ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LYEL...
Open
8,00 US$
High
8,44 US$
Low
7,76 US$
Mkt. cap
200,70 მლნ.
Avg. vol.
149,51 ათ.
Volume
324,99 ათ.
52-wk high
45,00 US$
52-wk low
7,32 US$
EPS
-12,01 US$
Beta
-0,03
Shares outstanding
24,50 მლნ.
No. of employees
161
Open
8,00 US$
High
8,44 US$
Low
7,76 US$
Mkt. cap
200,70 მლნ.
Avg. vol.
149,51 ათ.
Volume
324,99 ათ.
52-wk high
45,00 US$
52-wk low
7,32 US$
EPS
-12,01 US$
Beta
-0,03
Shares outstanding
24,50 მლნ.
No. of employees
161
News stories
From web sources and news partners
ad-hoc-news.de
·
2 საათის წინ
Lyell Immunopharma CMO sells 422 shares: USD 40.86 target for Lyell Immunopharma stock
ad-hoc-news.de
·
2 დღის წინ
Lyell advances LYL273: what it means for Lyell Immunopharma stock
Profile
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
About Lyell Immunopharma Inc
CEO-
Employees161
Founded2018
HeadquartersSouth San Francisco, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websitelyell.com